Pleural Mesothelioma
Information
- Disease name
- Pleural Mesothelioma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04334759 | Active, not recruiting | Phase 3 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | February 18, 2021 | December 2025 |
| NCT04914897 | Active, not recruiting | Phase 2 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | September 23, 2021 | January 22, 2025 |
| NCT04040231 | Active, not recruiting | Phase 1 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | July 24, 2019 | July 2024 |
| NCT00299962 | Completed | Phase 1 | Gene Therapy for Pleural Malignancies | March 2006 | October 2009 |
| NCT04430842 | Completed | Phase 1 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | July 20, 2020 | December 22, 2022 |
| NCT01160458 | Completed | Phase 2 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | June 2, 2010 | February 24, 2017 |
| NCT02414945 | Completed | Phase 1/Phase 2 | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | May 15, 2015 | October 2020 |
| NCT02585362 | Completed | N/A | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | March 2016 | October 2018 |
| NCT04324437 | Completed | N/A | eRAPID: Online Symptom Reporting in Lung Cancer | July 20, 2020 | December 31, 2023 |
| NCT02899195 | Completed | Phase 2 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma | June 13, 2017 | June 29, 2023 |
| NCT00165516 | Completed | Phase 2 | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate | January 2004 | December 2009 |
| NCT00165555 | Completed | Phase 1 | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | August 1999 | November 2009 |
| NCT06416930 | Not yet recruiting | Phase 2 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | June 20, 2024 | June 20, 2029 |
| NCT06155279 | Not yet recruiting | Phase 2 | Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) | June 2024 | December 2026 |
| NCT05538806 | Recruiting | TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study | August 1, 2023 | March 31, 2028 | |
| NCT05714553 | Recruiting | Phase 1/Phase 2 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | March 8, 2023 | January 2025 |
| NCT05910112 | Recruiting | Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention | September 1, 2020 | August 1, 2024 | |
| NCT05930665 | Recruiting | Phase 2 | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | November 1, 2023 | July 2026 |
| NCT02707666 | Recruiting | Phase 1 | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | February 25, 2016 | December 20, 2025 |
| NCT04823741 | Recruiting | Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | February 11, 2022 | February 11, 2026 | |
| NCT06410625 | Recruiting | N/A | Evaluation of Response by FLT PET in Mesothelioma | April 1, 2024 | July 1, 2025 |
| NCT06362369 | Recruiting | Phase 1/Phase 2 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | May 20, 2024 | December 31, 2028 |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT05628376 | Recruiting | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | December 4, 2023 | May 2034 | |
| NCT05337735 | Suspended | Phase 2 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | August 5, 2022 | April 1, 2025 |
| NCT04042480 | Terminated | Phase 1 | A Study of SGN-CD228A in Advanced Solid Tumors | September 3, 2019 | March 9, 2023 |
| NCT04106973 | Terminated | Mesothelioma Early Detection by VOCs | June 5, 2019 | January 1, 2022 | |
| NCT00895648 | Terminated | Phase 2 | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma | January 2009 | October 2012 |
| NCT00859495 | Terminated | Phase 2 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | February 2008 | February 2012 |
| NCT00165503 | Terminated | Phase 2 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | April 2004 | July 2010 |
| NCT05077111 | Unknown status | Phase 4 | A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia | January 15, 2020 | October 15, 2021 |
| NCT02588131 | Unknown status | Phase 2 | A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) | October 2015 | March 2018 |
| NCT03210298 | Unknown status | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | January 2016 | September 2022 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0100002
- OrphaNumber from OrphaNet (Orphanet)
- 50251